BridgeBio Pharma is a biopharmaceutical company to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. Co.'s pipeline includes: Acoramidis (Eidos), which is an oral small molecule Transthyretin (TTR) stabilizer for the treatment of TTR amyloidosis; Low-dose Infigratinib, which is an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of achondroplasia; BBP-418, which is a small molecule substrate replacement therapy for the treatment of Limb Girdle Muscular Dystrophy Type 2I; and BBP-812, which is an adeno-associated virus gene therapy for the treatment of Canavan Disease. The BBIO average annual return since 2019 is shown above.
The Average Annual Return on the BBIO average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether BBIO average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the BBIO average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|